Global Wilson's Disease Treatment Market is Estimated to Witness Strong Growth Due to Increasing Disease Prevalence and Rising Government Support
The Global Wilson's Disease Treatment Market is estimated to be valued at USD 591.2 Mn in 2024, exhibiting a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.The market is set to gain from the rising prevalence of Wilson's disease worldwide. Furthermore, growing government support in the form of funding for rare disease treatment research will provide market players with promising opportunities.
Market Dynamics:
Increasing Disease Prevalence: In August 2021, according to the National Library of Medicine Wilson's disease affects approximately 1 in 30,000 people globally. The growing patient pool suffering from this rare genetic disorder is a major driver expected to boost the demand for treatment drugs and therapies. Government Support Programs: Various governments are launching national plans and programs to boost rare disease research. This includes funding for clinical trials of new drug candidates and partnerships with pharmaceutical companies. For instance, the National Organization for Rare Disorders in the U.S. provides grants to study treatments for conditions like Wilson's disease. Favorable reimbursement policies are also aiding the market's growth.
Growing Prevalence of Wilson's Disease
Wilson's disease is a rare genetic disorder characterized by too much copper building up in the liver, brain, and other vital organs. According to statistics by the National Organization for Rare Disorders (NORD), in February 2020, the prevalence of Wilson's disease is estimated to be around 1 in 30,000 people worldwide. However, some regions have a significantly higher prevalence. For instance, it is as high as 1 in 7,000-14,000 in Australia and certain parts of Europe. The increasing cases of Wilson's disease globally is directly fueling the demand for effective treatment options and drugs.
Advancements in Treatment Options
The market is also witnessing strong growth due to ongoing research and development activities leading to advancements in Wilson's disease treatment options. Several new drug formulations and drug delivery methods are being explored which offer improved efficacy and safety. For example, novel nanoparticle-based drug delivery systems are being developed which allow targeted delivery of medication to affected organs. Similarly, new copper-chelating agents are in the pipeline that promises better removal of excess copper from the body. The introduction of these innovative treatment solutions is working as a major demand enabler in the market.
Lack of Disease Awareness
One of the major challenges faced by the Wilson's disease treatment market is lack of adequate awareness about the condition among general public as well as healthcare professionals. Since Wilson's disease is a rare genetic disorder, there exists a significant lack of understanding about its causes, symptoms and importance of early diagnosis and management. This acts as a key restraint as many cases still remain undiagnosed. Growing patients usually get misdiagnosed initially which leads to delayed treatment initiation. Campaigns to boost disease awareness through patient advocacy groups and pharmaceutical companies can help address this issue to some extent.
High Cost of Advanced Therapies
The cost of treatment, especially for advanced therapies, acts as another key hurdle in the growth of the Wilson's disease treatment market. While zinc and penicillamine remain as first line therapies globally, they have issues related to tolerance and long term adherence. Newer copper-chelating drugs and other novel treatment methods are much more expensive. This makes advanced solutions unaffordable for many patients, especially in price-sensitive developing markets. Lack of comprehensive insurance coverage for rare diseases further aggravates the cost challenges.
Developing Markets
Emerging economies in Asia Pacific and Latin America with their huge patient populations represent key growth opportunities. The availability and affordability of generic drugs in these regions provides scope to make essential Wilson's disease treatments accessible to more patients. Also, improving healthcare infrastructure and rising medical expenditures are expected to boost the demand. Governments are also focusing on rare diseases, which is creating a conducive environment. Market players can gain by expanding into high potential developing countries through appropriate pricing strategies and partnerships with local players.
Combination Therapies
Combining copper-chelating agents with other medications holds promise as a new avenue for manufacturers. Studies show that dual therapy with zinc along with penicillamine or trientine leads to better outcomes. Similarly, adding alpha-lipoic acid (ALA) as an adjunct therapy can potentially enhance treatment efficacy. Market players are investigating opportunities around developing fixed-dose combination products and new combinations through licensing deals. This represents a viable opportunity to offer more effective options and also sustain growth in the mature markets.
Link:
Key Developments:
- In October 2024, Ultragenyx, a pharmaceutical company, announced promising outcomes from Stage 1 of the Phase 1/2/3 Cyprus2+ study of UX701 gene therapy for Wilson’s disease. The therapy demonstrated significant clinical activity and improved copper metabolism, with several patients discontinuing standard-of-care treatments across all three dose cohorts. A new cohort with a higher dose and optimized immunomodulation will be added to enhance efficacy, with the goal of transitioning most patients off standard treatments before moving to the randomized placebo-controlled stage.
- In October 2024, Monopar Therapeutics, a clinical-stage biotechnology company, secured an exclusive worldwide license from Alexion, AstraZeneca Rare Disease, for ALXN-1840 (bis-choline tetrathiomolybdate), a Phase 3 drug candidate for Wilson’s disease. Monopar will lead all future development and commercialization efforts. CEO Dr. Chandler Robinson, who has a deep connection to Wilson’s disease research and advocacy, was instrumental in advancing ALXN-1840 from laboratory research to clinical trials. Alexion had discontinued the program in 2023 following a review of Phase II trial results and regulatory feedback.
- In August 2021, Vivet Therapeutics, a biotechnology company, and Pfizer a pharmaceutical company, announced that the U.S. FDA had granted Fast Track designation to VTX-801, a clinical-stage gene therapy for Wilson’s disease, a rare genetic disorder affecting copper regulation in the liver and other tissues. The designation aims to expedite the development and review of treatments for serious conditions with unmet medical needs. VTX-801 is set to be evaluated in a Phase 1/2 trial to assess its safety, tolerability, and pharmacological effects in adults.
Key Player:
Valeant Pharmaceuticals International, Merck & Co, Tsumura & Co, VHB Life Science Inc., Teva Pharmaceuticals USA Inc., Wilson's Therapeutics AB, Noble Pharma Co. Ltd, Kadmon Holdings Inc., Zydus Cadila, Mylan N.V., Hikma Pharmaceuticals, Sandoz (a Novartis division), Aurobindo Pharma, Amgen Inc., and Pfizer Inc.
